Neuronetics Overview
- Year Founded
-
2001
- Status
-
Public
- Employees
-
203
- Stock Symbol
-
STIM
- Investments
-
1
- Share Price
-
$0.80
- (As of Monday Closing)
Neuronetics General Information
Description
Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulations, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.
Contact Information
Website
www.neurostar.comCorporate Office
- 3222 Phoenixville Pike
- Malvern, PA 19355
- United States
Corporate Office
- 3222 Phoenixville Pike
- Malvern, PA 19355
- United States
Neuronetics Timeline
Neuronetics Stock Performance
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.80 | $0.85 | $0.66 - $5.07 | $24.2M | 30.3M | 416K | -$1.11 |
Neuronetics Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 67,924 | 87,288 | 151,128 | 54,567 |
| Revenue | 72,065 | 71,348 | 65,206 | 55,312 |
| EBITDA | (26,132) | (23,959) | (32,960) | (27,014) |
| Net Income | (32,473) | (30,189) | (37,159) | (31,193) |
| Total Assets | 96,813 | 115,831 | 116,884 | 141,223 |
| Total Debt | 62,622 | 62,474 | 39,745 | 39,544 |
Neuronetics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Neuronetics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Neuronetics Comparisons
Industry
Financing
Details
Neuronetics Competitors (10)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Inspire Medical Systems | Formerly VC-backed | Golden Valley, MN | ||||
| Curonix | Private Equity-Backed | Pompano Beach, FL | ||||
| MagVenture | Corporation | Farum, Denmark | ||||
| Newronika | Venture Capital-Backed | Cologno Monzese, Italy | ||||
| Flow Neuroscience | Venture Capital-Backed | Malmö, Sweden |
Neuronetics Patents
Neuronetics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20230414960-A1 | Motor threshold detection device for use with a magnetic stimulation system | Pending | 24-Jun-2022 | ||
| US-20210228898-A1 | Magnetic stimulation coils and ferromagnetic components for treatment and diagnostic procedures | Pending | 20-Feb-2018 | ||
| US-20190255346-A1 | Magnetic stimulation coils and ferromagnetic components for treatment and diagnostic procedures | Active | 20-Feb-2018 | ||
| US-11000693-B2 | Magnetic stimulation coils and ferromagnetic components for treatment and diagnostic procedures | Active | 20-Feb-2018 | ||
| EP-3755422-A1 | Magnetic stimulation coils and ferromagnetic components for treatment and diagnostic procedures | Pending | 20-Feb-2018 | A61N2/006 |
Neuronetics Executive Team (33)
| Name | Title | Board Seat |
|---|---|---|
| Keith Sullivan | Chief Executive Officer & Board Member | |
| Lisa Metzner | Senior Vice President & Chief Marketing Officer | |
| Sara Grubbs | Chief Revenue Officer & Senior Vice President | |
| Cindy Varughese | Director, Regulatory Affairs | |
| W. Macan JD | Executive Vice President & General Counsel, Legal |
Neuronetics Board Members (25)
| Name | Representing | Role | Since |
|---|---|---|---|
| Brian Farley | Self | Chairman & Board Member | |
| Bruce Shook | Self | Board Member | |
| Glenn Muir MD | Self | Board Member | |
| John Bakewell | Self | Board Member | |
| Joseph Capper | Self | Board Member |
Neuronetics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Neuronetics Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Greenbrook TMS | 12-Aug-2024 | Clinics/Outpatient Services |
Neuronetics ESG
Risk Overview
Risk Rating
Updated April, 01, 2022
43.31 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,912
Rank
Percentile
Healthcare
Industry
of 616
Rank
Percentile
Medical Devices
Subindustry
of 221
Rank
Percentile
Neuronetics FAQs
-
When was Neuronetics founded?
Neuronetics was founded in 2001.
-
Who is the founder of Neuronetics?
Norman Weldon Ph.D is the founder of Neuronetics.
-
Who is the CEO of Neuronetics?
Keith Sullivan is the CEO of Neuronetics.
-
Where is Neuronetics headquartered?
Neuronetics is headquartered in Malvern, PA.
-
What is the size of Neuronetics?
Neuronetics has 203 total employees.
-
What industry is Neuronetics in?
Neuronetics’s primary industry is Therapeutic Devices.
-
Is Neuronetics a private or public company?
Neuronetics is a Public company.
-
What is Neuronetics’s stock symbol?
The ticker symbol for Neuronetics is STIM.
-
What is the current stock price of Neuronetics?
As of 07-Oct-2024 the stock price of Neuronetics is $0.80.
-
What is the current market cap of Neuronetics?
The current market capitalization of Neuronetics is $24.2M.
-
What is Neuronetics’s current revenue?
The trailing twelve month revenue for Neuronetics is $72.1M.
-
Who are Neuronetics’s competitors?
Inspire Medical Systems, Curonix, MagVenture, Newronika, and Flow Neuroscience are some of the 10 competitors of Neuronetics.
-
What is Neuronetics’s annual earnings per share (EPS)?
Neuronetics’s EPS for 12 months was -$1.11.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
